Vinay Nidadavolu, MD
Pulmonary Disease · Louisville, KYNPI 1750660734
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $973 and has fallen 61.4% since, to $376 in 2023. That places this record below the midpoint for pulmonary disease clinicians in KY, where the typical reported total is $4,124.
Across 228 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$736
- Pfizer$576
- AstraZeneca$449
- Boehringer Ingelheim$419
- Grifols USA, LLC$244
- Regeneron Healthcare Solutions, Inc.$147
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,70498%
- Education$762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 58 | $736 |
| Pfizer | 35 | $576 |
| AstraZeneca | 20 | $449 |
| Boehringer Ingelheim | 22 | $419 |
| Grifols USA, LLC | 13 | $244 |
| Regeneron Healthcare Solutions, Inc. | 7 | $147 |
| Insmed, Inc. | 5 | $127 |
| Mallinckrodt Hospital Products Inc. | 4 | $112 |
| Mylan Specialty L.p. | 7 | $102 |
| Actelion Pharmaceuticals US, Inc. | 5 | $94 |
| Genentech USA, Inc. | 5 | $85 |
| Electromed, Inc. | 7 | $80 |
| CSL Behring | 5 | $80 |
| Jazz Pharmaceuticals Inc. | 5 | $69 |
| Sanofi | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Chiesi USA, Inc. | 2 | $28 |
| Paratek Pharmaceuticals, Inc. | 2 | $28 |
| Amgen | 2 | $27 |
| Gilead | 2 | $25 |
| Harmony Biosciences LLC | 2 | $23 |
| CMP Pharma, Inc. | 1 | $22 |
| Abbott | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| UCB, Inc. | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| Ambu Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Philips North America LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STIOLTO RESPIMAT$125
- SPIRIVA RESPIMAT$125
How this compares
$3,780 in reported general payments places this provider in the 45th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pirfenidone | 12 | $73,392 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $34,647 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $17,910 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $16,459 |
| Spiriva RespimatTiotropium Bromide | 15 | $9,614 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $1,276 |
| Montelukast Sodium | 55 | $267 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 11 | $36 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $736 | $51,10675 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $419 | $27,52436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Louisville
- John McConnellLouisville$864K
- Harold HallerLouisville$340K
- Samantha BaahLouisville$226K
- Karim El-KershLouisville$180K
- Josephine MeiLouisville$101K
- Maroun GhosseinLouisville$34K
- Moutaz Al NabhanLouisville$24K
- Sally SulimanLouisville$21K
- Mark EsterleLouisville$19K
- Kenneth AndersonLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.